Related Experiment Videos
Cyclin E expression in operable breast cancer quantified using real-time RT-PCR: a comparative study with
Piotr Potemski1, Elzbieta Pluciennik, Andrzej K Bednarek
1Department of Chemotherapy, Medical University of Lodz, 4 Paderewski Street, 93-509 Lodz, Poland. piotrpo@mp.pl
Japanese Journal of Clinical Oncology
|March 8, 2006
Summary
Immunostaining is a more reliable method than real-time RT-PCR for assessing cyclin E expression in breast cancer, as it predicts patient survival, unlike RT-PCR.
Area of Science:
- Oncology
- Molecular Biology
- Biomarker Research
Background:
- Cyclin E is a key regulator of the cell cycle.
- Accurate assessment of cyclin E is crucial for breast cancer prognosis.
Purpose of the Study:
- To compare cyclin E expression levels using real-time RT-PCR and immunostaining in operable breast cancer.
- To investigate the prognostic relevance of cyclin E in breast cancer patients.
Main Methods:
- Retrospective analysis of 124 invasive ductal breast cancer tissue specimens.
- Quantification of cyclin E expression via real-time RT-PCR and immunostaining.
Main Results:
- High cyclin E expression was observed in 40.3% (RT-PCR) and 59.7% (immunostaining) of samples.
- Immunostaining revealed cyclin E as an independent negative prognostic factor in node-positive patients (HR 3.1, P=0.045).
- RT-PCR results did not predict patient survival.
Conclusions:
- Significant disagreement exists between real-time RT-PCR and immunostaining for cyclin E assessment.
- Immunostaining appears to be a more reliable method for evaluating cyclin E in breast cancer.